We are live on ! Find out more
Lazard Asset Management

Lazard Asset Management Portfolio holdings

AUM $60.8B
1-Year Est. Return 22.47%
This Fund
S&P 500
This Quarter Est. Return
+0.1%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$68.4B
AUM Growth
-$6.42B
Cap. Flow
-$9.95B
Cap. Flow %
-14.55%
Top 10 Hldgs %
25.74%
Holding
2,605
New
281
Increased
825
Reduced
894
Closed
234

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$433M
2
MRK icon
Merck
MRK
+$286M
3
J icon
Jacobs Solutions
J
+$265M
4
EFX icon
Equifax
EFX
+$253M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$240M

Sector Composition

Rank Sector Weight
1 Technology 26.04%
2 Financials 14.64%
3 Healthcare 12%
4 Industrials 10.54%
5 Consumer Discretionary 9.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JKHY icon
2226
Jack Henry & Associates
JKHY
$11.1B
-4
Closed
JSPR icon
2227
Jasper Therapeutics
JSPR
$20.2M
$0 ﹤0.01%
17
KEQU icon
2228
Kewaunee Scientific
KEQU
$107M
-22
Closed
KGS icon
2229
Kodiak Gas Services
KGS
$5.86B
-55
Closed -$1K
KMX icon
2230
CarMax
KMX
$8.29B
-23
Closed -$1K
KPTI icon
2231
Karyopharm Therapeutics
KPTI
$44.4M
-105
Closed -$1K
KWR icon
2232
Quaker Houghton
KWR
$2.89B
-4,041
Closed -$680K
LAD icon
2233
Lithia Motors
LAD
$8.31B
-791
Closed -$251K
LAKE icon
2234
Lakeland Industries
LAKE
$117M
-384
Closed -$7K
MZTI
2235
The Marzetti Company
MZTI
$3.02B
-614
Closed -$108K
LBTYK icon
2236
Liberty Global Class C
LBTYK
$3.63B
$0 ﹤0.01%
59
LCTX icon
2237
Lineage Cell Therapeutics
LCTX
$279M
$0 ﹤0.01%
148
LEA icon
2238
Lear
LEA
$6.17B
-6,710
Closed -$732K
LEGN icon
2239
Legend Biotech
LEGN
$3.68B
$0 ﹤0.01%
9
LFCR icon
2240
Lifecore Biomedical
LFCR
$165M
-277
Closed -$1K
LFUS icon
2241
Littelfuse
LFUS
$11.3B
-3,097
Closed -$821K
LINC icon
2242
Lincoln Educational Services
LINC
$1.37B
-17,757
Closed -$212K
LLYVK icon
2243
Liberty Live Group Series C
LLYVK
$9.53B
$0 ﹤0.01%
10
LMB icon
2244
Limbach Holdings
LMB
$873M
-5,775
Closed -$437K
LOB icon
2245
Live Oak Bancshares
LOB
$2.03B
$0 ﹤0.01%
+7
New +$315
LVO icon
2246
LiveOne
LVO
$60.9M
-452
Closed -$4K
LXEO icon
2247
Lexeo Therapeutics
LXEO
$330M
$0 ﹤0.01%
33
LXP icon
2248
LXP Industrial Trust
LXP
$3.56B
$0 ﹤0.01%
20
-70
-78% -$3.24K
LYEL icon
2249
Lyell Immunopharma
LYEL
$315M
$0 ﹤0.01%
9
M icon
2250
Macy's
M
$6.83B
$0 ﹤0.01%
51
-55,745
-100% -$888K

Similar funds

Lazard Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Lazard Asset Management held 2,605 positions worth $68.4B, down 8.6% from $74.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Lazard Asset Management withdrew a net $9.95B in Q4 2024, closing 234 positions and reducing 894 holdings. Its most notable exit was Atlantica Sustainable Infrastructure plc Ordinary Shares, an estimated $210M position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lazard Asset Management opened a new position in Vaxcyte worth $39.8M.

  • Lazard Asset Management's largest Q4 2024 buy was Vaxcyte: 486,764 shares worth $39.8M.
  • Lazard Asset Management added most to Eli Lilly in Q4 2024, an estimated $433M increase.
  • Lazard Asset Management's biggest Q4 2024 reduction was Microsoft, cutting an estimated $710M.
  • Lazard Asset Management fully exited Atlantica Sustainable Infrastructure plc Ordinary Shares in Q4 2024, selling an estimated $210M.
  • Lazard Asset Management's ten largest holdings make up 26% of its $68.4B portfolio in Q4 2024.
  • Lazard Asset Management opened 281 new positions and closed 234 in Q4 2024.
  • Lazard Asset Management's portfolio value fell 8.6% quarter-over-quarter to $68.4B.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.